-
1
-
-
33846404966
-
Expanding priorities - confronting chronic disease in countries with low income
-
Anderson GF, Chu E. Expanding priorities - confronting chronic disease in countries with low income. N Engl J Med 2007; 356: 209-11.
-
(2007)
N Engl J Med
, vol.356
, pp. 209-211
-
-
Anderson, G.F.1
Chu, E.2
-
2
-
-
33947533514
-
One-year cardiovascular event rates in outpatients with atherothrombosis
-
Steg PG, Bhatt DL, Wilson PWF, D'Agostino R, Ohman EM, Röther J, Liau C, Hirsch AT, Mas J, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-206.
-
(2007)
JAMA
, vol.297
, pp. 1197-1206
-
-
Steg, P.G.1
Bhatt, D.L.2
Wilson, P.W.F.3
D'Agostino, R.4
Ohman, E.M.5
Röther, J.6
Liau, C.7
Hirsch, A.T.8
Mas, J.9
Ikeda, Y.10
Pencina, M.J.11
Goto, S.12
-
3
-
-
34247869037
-
Autopsy prevalence of coronary atherosclerosis in patients with fatal stroke
-
Gongora-Rivera F, Labreuche J, Jaramillo A, Steg PG, Hauw J, Amarenco P. Autopsy prevalence of coronary atherosclerosis in patients with fatal stroke. Stroke 2007; 38: 1203-10.
-
(2007)
Stroke
, vol.38
, pp. 1203-1210
-
-
Gongora-Rivera, F.1
Labreuche, J.2
Jaramillo, A.3
Steg, P.G.4
Hauw, J.5
Amarenco, P.6
-
4
-
-
77950938605
-
Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS study
-
Calvet D, Touzé E, Varenne O, Sablayrolles J, Weber S, Mas J. Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS study. Circulation 2010; 121: 1623-9.
-
(2010)
Circulation
, vol.121
, pp. 1623-1629
-
-
Calvet, D.1
Touzé, E.2
Varenne, O.3
Sablayrolles, J.4
Weber, S.5
Mas, J.6
-
5
-
-
79451471579
-
Prevalence of coronary atherosclerosis in patients with cerebral infarction
-
Amarenco P, Lavallée PC, Labreuche J, Ducrocq G, Juliard J, Feldman L, Cabrejo L, Meseguer E, Guidoux C, Adraï V, Ratani S, Kusmierek J, Lapergue B, Klein IF, Gongora-Rivera F, Jaramillo A, Mazighi M, Touboul P, Steg PG. Prevalence of coronary atherosclerosis in patients with cerebral infarction. Stroke 2011; 42: 22-9.
-
(2011)
Stroke
, vol.42
, pp. 22-29
-
-
Amarenco, P.1
Lavallée, P.C.2
Labreuche, J.3
Ducrocq, G.4
Juliard, J.5
Feldman, L.6
Cabrejo, L.7
Meseguer, E.8
Guidoux, C.9
Adraï, V.10
Ratani, S.11
Kusmierek, J.12
Lapergue, B.13
Klein, I.F.14
Gongora-Rivera, F.15
Jaramillo, A.16
Mazighi, M.17
Touboul, P.18
Steg, P.G.19
-
6
-
-
42649136576
-
Prevalence of coronary artery disease in Japanese patients with cerebral infarction: impact of metabolic syndrome and intracranial large artery atherosclerosis
-
Hoshino A, Nakamura T, Enomoto S, Kawahito H, Kurata H, Nakahara Y, Ijichi T. Prevalence of coronary artery disease in Japanese patients with cerebral infarction: impact of metabolic syndrome and intracranial large artery atherosclerosis. Circ J 2008; 72: 404-8.
-
(2008)
Circ J
, vol.72
, pp. 404-408
-
-
Hoshino, A.1
Nakamura, T.2
Enomoto, S.3
Kawahito, H.4
Kurata, H.5
Nakahara, Y.6
Ijichi, T.7
-
7
-
-
0028342542
-
Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62years of age
-
Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62years of age. Am J Cardiol 1994; 74: 64-5.
-
(1994)
Am J Cardiol
, vol.74
, pp. 64-65
-
-
Aronow, W.S.1
Ahn, C.2
-
8
-
-
0037072453
-
Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study
-
Rioufol G, Finet G, Ginon I, André-Fouët X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-8.
-
(2002)
Circulation
, vol.106
, pp. 804-808
-
-
Rioufol, G.1
Finet, G.2
Ginon, I.3
André-Fouët, X.4
Rossi, R.5
Vialle, E.6
Desjoyaux, E.7
Convert, G.8
Huret, J.F.9
Tabib, A.10
-
9
-
-
37249068049
-
Platelet activation and atherothrombosis
-
Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
-
(2007)
N Engl J Med
, vol.357
, pp. 2482-2494
-
-
Davì, G.1
Patrono, C.2
-
10
-
-
60049093774
-
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance"
-
Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davì G, Patrono C. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 2009; 53: 667-77.
-
(2009)
J Am Coll Cardiol
, vol.53
, pp. 667-677
-
-
Santilli, F.1
Rocca, B.2
De Cristofaro, R.3
Lattanzio, S.4
Pietrangelo, L.5
Habib, A.6
Pettinella, C.7
Recchiuti, A.8
Ferrante, E.9
Ciabattoni, G.10
Davì, G.11
Patrono, C.12
-
11
-
-
11144246091
-
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials
-
on behalf of the Dipyridamole in Stroke Collaboration.
-
Leonardi-Bee J, Bath PM, Bousser M, Davalos A, Diener H, Guiraud-Chaumeil B, Sivenius J, Yatsu F, Dewey ME, on behalf of the Dipyridamole in Stroke Collaboration. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36: 162-8.
-
(2005)
Stroke
, vol.36
, pp. 162-168
-
-
Leonardi-Bee, J.1
Bath, P.M.2
Bousser, M.3
Davalos, A.4
Diener, H.5
Guiraud-Chaumeil, B.6
Sivenius, J.7
Yatsu, F.8
Dewey, M.E.9
-
12
-
-
0037114872
-
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication
-
Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90: 1314-9.
-
(2002)
Am J Cardiol
, vol.90
, pp. 1314-1319
-
-
Thompson, P.D.1
Zimet, R.2
Forbes, W.P.3
Zhang, P.4
-
13
-
-
77953661111
-
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction/clinical perspective
-
Jeong Y, Hwang J, Kim I, Park Y, Hwang S, Lee S, Kwak CH, Park S. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction/clinical perspective. Circ Cardiovasc Interv 2010; 3: 17-26.
-
(2010)
Circ Cardiovasc Interv
, vol.3
, pp. 17-26
-
-
Jeong, Y.1
Hwang, J.2
Kim, I.3
Park, Y.4
Hwang, S.5
Lee, S.6
Kwak, C.H.7
Park, S.8
-
14
-
-
77956884231
-
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial
-
Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-68.
-
(2010)
Lancet Neurol
, vol.9
, pp. 959-968
-
-
Shinohara, Y.1
Katayama, Y.2
Uchiyama, S.3
Yamaguchi, T.4
Handa, S.5
Matsuoka, K.6
Ohashi, Y.7
Tanahashi, N.8
Yamamoto, H.9
Genka, C.10
Kitagawa, Y.11
Kusuoka, H.12
Nishimaru, K.13
Tsushima, M.14
Koretsune, Y.15
Sawada, T.16
Hamada, C.17
-
15
-
-
34948875324
-
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease
-
Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-7.
-
(2007)
J Am Coll Cardiol
, vol.50
, pp. 1541-1547
-
-
Angiolillo, D.J.1
Bernardo, E.2
Sabaté, M.3
Jimenez-Quevedo, P.4
Costa, M.A.5
Palazuelos, J.6
Hernández-Antolin, R.7
Moreno, R.8
Escaned, J.9
Alfonso, F.10
Bañuelos, C.11
Guzman, L.A.12
Bass, T.A.13
Macaya, C.14
Fernandez-Ortiz, A.15
-
16
-
-
33749339075
-
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
-
Hulot J, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-7.
-
(2006)
Blood
, vol.108
, pp. 2244-2247
-
-
Hulot, J.1
Bura, A.2
Villard, E.3
Azizi, M.4
Remones, V.5
Goyenvalle, C.6
Aiach, M.7
Lechat, P.8
Gaussem, P.9
-
17
-
-
69249219296
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
-
Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
-
(2009)
JAMA
, vol.302
, pp. 849-857
-
-
Shuldiner, A.R.1
O'Connell, J.R.2
Bliden, K.P.3
Gandhi, A.4
Ryan, K.5
Horenstein, R.B.6
Damcott, C.M.7
Pakyz, R.8
Tantry, U.S.9
Gibson, Q.10
Pollin, T.I.11
Post, W.12
Parsa, A.13
Mitchell, B.D.14
Faraday, N.15
Herzog, W.16
Gurbel, P.A.17
-
18
-
-
78049326068
-
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
-
Mega JL, Simon T, Collet J, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot J, Kastrati A, Montalescot G, Neumann F, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821-30.
-
(2010)
JAMA
, vol.304
, pp. 1821-1830
-
-
Mega, J.L.1
Simon, T.2
Collet, J.3
Anderson, J.L.4
Antman, E.M.5
Bliden, K.6
Cannon, C.P.7
Danchin, N.8
Giusti, B.9
Gurbel, P.10
Horne, B.D.11
Hulot, J.12
Kastrati, A.13
Montalescot, G.14
Neumann, F.15
Shen, L.16
Sibbing, D.17
Steg, P.G.18
Trenk, D.19
Wiviott, S.D.20
Sabatine, M.S.21
more..
-
19
-
-
34250714831
-
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
-
Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007; 5: 1545-51.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 1545-1551
-
-
Sugidachi, A.1
Ogawa, T.2
Kurihara, A.3
Hagihara, K.4
Jakubowski, J.A.5
Hashimoto, M.6
Niitsu, Y.7
Asai, F.8
-
20
-
-
77955677366
-
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)
-
Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010; 160: 65-72.
-
(2010)
Am Heart J
, vol.160
, pp. 65-72
-
-
Leonardi, S.1
Rao, S.V.2
Harrington, R.A.3
Bhatt, D.L.4
Gibson, C.M.5
Roe, M.T.6
Kochman, J.7
Huber, K.8
Zeymer, U.9
Madan, M.10
Gretler, D.D.11
McClure, M.W.12
Paynter, G.E.13
Thompson, V.14
Welsh, R.C.15
-
21
-
-
73949157474
-
Platelet thrombin receptor antagonism and atherothrombosis
-
Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010; 31: 17-28.
-
(2010)
Eur Heart J
, vol.31
, pp. 17-28
-
-
Angiolillo, D.J.1
Capodanno, D.2
Goto, S.3
-
22
-
-
28344436780
-
Protease-activated receptors in hemostasis, thrombosis and vascular biology
-
Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-14.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 1800-1814
-
-
Coughlin, S.R.1
-
23
-
-
61849180442
-
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
-
Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-28.
-
(2009)
Lancet
, vol.373
, pp. 919-928
-
-
Becker, R.C.1
Moliterno, D.J.2
Jennings, L.K.3
Pieper, K.S.4
Pei, J.5
Niederman, A.6
Ziada, K.M.7
Berman, G.8
Strony, J.9
Joseph, D.10
Mahaffey, K.W.11
Van de Werf, F.12
Veltri, E.13
Harrington, R.A.14
-
24
-
-
67749086022
-
The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease
-
Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009; 102: 111-9.
-
(2009)
Thromb Haemost
, vol.102
, pp. 111-119
-
-
Serebruany, V.L.1
Kogushi, M.2
Dastros-Pitei, D.3
Flather, M.4
Bhatt, D.L.5
-
25
-
-
78149355554
-
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
-
Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010; 31: 2601-13.
-
(2010)
Eur Heart J
, vol.31
, pp. 2601-2613
-
-
Goto, S.1
Ogawa, H.2
Takeuchi, M.3
Flather, M.D.4
Bhatt, D.L.5
-
26
-
-
0032578960
-
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
-
Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35.
-
(1998)
Circulation
, vol.98
, pp. 2829-2835
-
-
Kong, D.F.1
Califf, R.M.2
Miller, D.P.3
Moliterno, D.J.4
White, H.D.5
Harrington, R.A.6
Tcheng, J.E.7
Lincoff, A.M.8
Hasselblad, V.9
Topol, E.J.10
-
27
-
-
77956922384
-
Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis
-
Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PWF, Alberts MJ, D'Agostino R, Liau C, Mas J, Röther J, Smith SC, Salette G, Contant CF, Massaro JM, Steg PG. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304: 1350-7.
-
(2010)
JAMA
, vol.304
, pp. 1350-1357
-
-
Bhatt, D.L.1
Eagle, K.A.2
Ohman, E.M.3
Hirsch, A.T.4
Goto, S.5
Mahoney, E.M.6
Wilson, P.W.F.7
Alberts, M.J.8
D'Agostino, R.9
Liau, C.10
Mas, J.11
Röther, J.12
Smith, S.C.13
Salette, G.14
Contant, C.F.15
Massaro, J.M.16
Steg, P.G.17
-
28
-
-
0037065502
-
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
-
Antithrombotic Trialists' Collaboration.
-
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
-
(2002)
BMJ
, vol.324
, pp. 71-86
-
-
-
29
-
-
65849268320
-
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
-
Antithrombotic Trialists' (ATT) Collaboration
-
Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
-
(2009)
Lancet
, vol.373
, pp. 1849-1860
-
-
-
30
-
-
27644531361
-
Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial
-
COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.
-
Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1622-32.
-
(2005)
Lancet
, vol.366
, pp. 1622-1632
-
-
Chen, Z.M.1
Pan, H.C.2
Chen, Y.P.3
Peto, R.4
Collins, R.5
Jiang, L.X.6
Xie, J.X.7
Liu, L.S.8
-
31
-
-
20144373281
-
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
-
Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
-
(2005)
N Engl J Med
, vol.352
, pp. 1179-1189
-
-
Sabatine, M.S.1
Cannon, C.P.2
Gibson, C.M.3
López-Sendón, J.L.4
Montalescot, G.5
Theroux, P.6
Claeys, M.J.7
Cools, F.8
Hill, K.A.9
Skene, A.M.10
McCabe, C.H.11
Braunwald, E.12
-
32
-
-
34547772153
-
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
-
Bassand J, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KAA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-660.
-
(2007)
Eur Heart J
, vol.28
, pp. 1598-1660
-
-
Bassand, J.1
Hamm, C.W.2
Ardissino, D.3
Boersma, E.4
Budaj, A.5
Fernández-Avilés, F.6
Fox, K.A.A.7
Hasdai, D.8
Ohman, E.M.9
Wallentin, L.10
Wijns, W.11
-
33
-
-
34547655744
-
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with
-
Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50: e1-157.
-
(2007)
J Am Coll Cardiol
, vol.50
-
-
Anderson, J.L.1
Adams, C.D.2
Antman, E.M.3
Bridges, C.R.4
Califf, R.M.5
Casey, D.E.6
Chavey, W.E.7
Fesmire, F.M.8
Hochman, J.S.9
Levin, T.N.10
Lincoff, A.M.11
Peterson, E.D.12
Theroux, P.13
Wenger, N.K.14
Wright, R.S.15
Smith, S.C.16
Jacobs, A.K.17
Adams, C.D.18
Anderson, J.L.19
Antman, E.M.20
more..
-
34
-
-
45949090749
-
Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
-
Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG. Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 670S-707S.
-
(2008)
Chest
, vol.133
-
-
Harrington, R.A.1
Becker, R.C.2
Cannon, C.P.3
Gutterman, D.4
Lincoff, A.M.5
Popma, J.J.6
Steg, G.7
Guyatt, G.H.8
Goodman, S.G.9
-
35
-
-
77956290748
-
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes
-
Mehta SR, Bassand J, Chrolavicius S, Diaz R, Eikelboom JW, Fox KAA, Granger CB, Jolly S, Joyner CD, Rupprecht H, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-42.
-
(2010)
N Engl J Med
, vol.363
, pp. 930-942
-
-
Mehta, S.R.1
Bassand, J.2
Chrolavicius, S.3
Diaz, R.4
Eikelboom, J.W.5
Fox, K.A.A.6
Granger, C.B.7
Jolly, S.8
Joyner, C.D.9
Rupprecht, H.10
Widimsky, P.11
Afzal, R.12
Pogue, J.13
Yusuf, S.14
-
36
-
-
77958005516
-
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
-
Mehta SR, Tanguay J, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht H, Budaj A, Avezum A. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-43.
-
(2010)
Lancet
, vol.376
, pp. 1233-1243
-
-
Mehta, S.R.1
Tanguay, J.2
Eikelboom, J.W.3
Jolly, S.S.4
Joyner, C.D.5
Granger, C.B.6
Faxon, D.P.7
Rupprecht, H.8
Budaj, A.9
Avezum, A.10
-
37
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
-
(2007)
N Engl J Med
, vol.357
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
Montalescot, G.4
Ruzyllo, W.5
Gottlieb, S.6
Neumann, F.7
Ardissino, D.8
De Servi, S.9
Murphy, S.A.10
Riesmeyer, J.11
Weerakkody, G.12
Gibson, C.M.13
Antman, E.M.14
-
38
-
-
77955690680
-
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial
-
e1.
-
Chin CT, Roe MT, Fox KAA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160: 16-22.e1.
-
(2010)
Am Heart J
, vol.160
, pp. 16-22
-
-
Chin, C.T.1
Roe, M.T.2
Fox, K.A.A.3
Prabhakaran, D.4
Marshall, D.A.5
Petitjean, H.6
Lokhnygina, Y.7
Brown, E.8
Armstrong, P.W.9
White, H.D.10
Ohman, E.M.11
-
39
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
Cannon, C.P.4
Emanuelsson, H.5
Held, C.6
Horrow, J.7
Husted, S.8
James, S.9
Katus, H.10
Mahaffey, K.W.11
Scirica, B.M.12
Skene, A.13
Steg, P.G.14
Storey, R.F.15
Harrington, R.A.16
Freij, A.17
Thorsén, M.18
-
40
-
-
0037132843
-
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials
-
Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98.
-
(2002)
Lancet
, vol.359
, pp. 189-198
-
-
Boersma, E.1
Harrington, R.A.2
Moliterno, D.J.3
White, H.4
Théroux, P.5
van de Werf, F.6
de Torbal, A.7
Armstrong, P.W.8
Wallentin, L.C.9
Wilcox, R.G.10
Simes, J.11
Califf, R.M.12
Topol, E.J.13
Simoons, M.L.14
-
41
-
-
66149124479
-
Early versus delayed, provisional eptifibatide in acute coronary syndromes
-
Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009; 360: 2176-90.
-
(2009)
N Engl J Med
, vol.360
, pp. 2176-2190
-
-
Giugliano, R.P.1
White, J.A.2
Bode, C.3
Armstrong, P.W.4
Montalescot, G.5
Lewis, B.S.6
van 't Hof, A.7
Berdan, L.G.8
Lee, K.L.9
Strony, J.T.10
Hildemann, S.11
Veltri, E.12
Van de Werf, F.13
Braunwald, E.14
Harrington, R.A.15
Califf, R.M.16
Newby, L.K.17
-
42
-
-
33645507439
-
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial
-
Kastrati A, Mehilli J, Neumann F, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-8.
-
(2006)
JAMA
, vol.295
, pp. 1531-1538
-
-
Kastrati, A.1
Mehilli, J.2
Neumann, F.3
Dotzer, F.4
ten Berg, J.5
Bollwein, H.6
Graf, I.7
Ibrahim, M.8
Pache, J.9
Seyfarth, M.10
Schühlen, H.11
Dirschinger, J.12
Berger, P.B.13
Schömig, A.14
-
43
-
-
44249120546
-
Facilitated PCI in patients with ST-elevation myocardial infarction
-
Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358: 2205-17.
-
(2008)
N Engl J Med
, vol.358
, pp. 2205-2217
-
-
Ellis, S.G.1
Tendera, M.2
de Belder, M.A.3
van Boven, A.J.4
Widimsky, P.5
Janssens, L.6
Andersen, H.R.7
Betriu, A.8
Savonitto, S.9
Adamus, J.10
Peruga, J.Z.11
Kosmider, M.12
Katz, O.13
Neunteufl, T.14
Jorgova, J.15
Dorobantu, M.16
Grinfeld, L.17
Armstrong, P.18
Brodie, B.R.19
Herrmann, H.C.20
more..
-
44
-
-
77952517848
-
Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with st-segment elevation myocardial infarction on short- and long-term clinical outcome
-
Ten Berg JM, van't Hof AW, Dill T, Heestermans T, van Werkum JW, Mosterd A, van Houwelingen G, Koopmans PC, Stella PR, Boersma E, Hamm C. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with st-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010; 55: 2446-55.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2446-2455
-
-
Ten Berg, J.M.1
van't Hof, A.W.2
Dill, T.3
Heestermans, T.4
van Werkum, J.W.5
Mosterd, A.6
van Houwelingen, G.7
Koopmans, P.C.8
Stella, P.R.9
Boersma, E.10
Hamm, C.11
-
45
-
-
85058720552
-
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) trial: study design and rationale
-
The TRA•CER Executive and Steering committee. e4.
-
The TRA•CER Executive and Steering committee. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) trial: study design and rationale. Am Heart J 2009; 158: 327-34.e4.
-
(2009)
Am Heart J
, vol.158
, pp. 327-334
-
-
-
46
-
-
71849119604
-
Intravenous platelet blockade with cangrelor during PCI
-
Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-41.
-
(2009)
N Engl J Med
, vol.361
, pp. 2330-2341
-
-
Bhatt, D.L.1
Lincoff, A.M.2
Gibson, C.M.3
Stone, G.W.4
McNulty, S.5
Montalescot, G.6
Kleiman, N.S.7
Goodman, S.G.8
White, H.D.9
Mahaffey, K.W.10
Pollack, C.V.11
Manoukian, S.V.12
Widimsky, P.13
Chew, D.P.14
Cura, F.15
Manukov, I.16
Tousek, F.17
Jafar, M.Z.18
Arneja, J.19
Skerjanec, S.20
Harrington, R.A.21
more..
-
47
-
-
71849087338
-
Platelet inhibition with cangrelor in patients undergoing PCI
-
Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-29.
-
(2009)
N Engl J Med
, vol.361
, pp. 2318-2329
-
-
Harrington, R.A.1
Stone, G.W.2
McNulty, S.3
White, H.D.4
Lincoff, A.M.5
Gibson, C.M.6
Pollack, C.V.7
Montalescot, G.8
Mahaffey, K.W.9
Kleiman, N.S.10
Goodman, S.G.11
Amine, M.12
Angiolillo, D.J.13
Becker, R.C.14
Chew, D.P.15
French, W.J.16
Leisch, F.17
Parikh, K.H.18
Skerjanec, S.19
Bhatt, D.L.20
more..
-
48
-
-
0030590746
-
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
-
CAPRIE Steering Committee.
-
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
-
(1996)
Lancet
, vol.348
, pp. 1329-1339
-
-
-
49
-
-
33645861080
-
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
-
Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak K, Mas J, Montalescot G, Pearson TA, Steg PG et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
-
(2006)
N Engl J Med
, vol.354
, pp. 1706-1717
-
-
Bhatt, D.L.1
Fox, K.A.A.2
Hacke, W.3
Berger, P.B.4
Black, H.R.5
Boden, W.E.6
Cacoub, P.7
Cohen, E.A.8
Creager, M.A.9
Easton, J.D.10
Flather, M.D.11
Haffner, S.M.12
Hamm, C.W.13
Hankey, G.J.14
Johnston, S.C.15
Mak, K.16
Mas, J.17
Montalescot, G.18
Pearson, T.A.19
Steg, P.G.20
more..
-
50
-
-
34247869852
-
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
-
Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak K, Mas J, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-8.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1982-1988
-
-
Bhatt, D.L.1
Flather, M.D.2
Hacke, W.3
Berger, P.B.4
Black, H.R.5
Boden, W.E.6
Cacoub, P.7
Cohen, E.A.8
Creager, M.A.9
Easton, J.D.10
Hamm, C.W.11
Hankey, G.J.12
Johnston, S.C.13
Mak, K.14
Mas, J.15
Montalescot, G.16
Pearson, T.A.17
Steg, P.G.18
Steinhubl, S.R.19
Weber, M.A.20
more..
-
52
-
-
76449090664
-
Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events
-
Hankey GJ, Eikelboom J. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 2010; 9: 273-84.
-
(2010)
Lancet Neurol
, vol.9
, pp. 273-284
-
-
Hankey, G.J.1
Eikelboom, J.2
-
53
-
-
65449173947
-
The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population
-
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici M, Mattle HP, Rothwell PM. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovasc Dis 2009; 27: 608-13.
-
(2009)
Cerebrovasc Dis
, vol.27
, pp. 608-613
-
-
Bousser, M.G.1
Amarenco, P.2
Chamorro, A.3
Fisher, M.4
Ford, I.5
Fox, K.6
Hennerici, M.7
Mattle, H.P.8
Rothwell, P.M.9
-
54
-
-
51449116270
-
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
-
Sacco RL, Diener H, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BPL, Chen S, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
-
(2008)
N Engl J Med
, vol.359
, pp. 1238-1251
-
-
Sacco, R.L.1
Diener, H.2
Yusuf, S.3
Cotton, D.4
Ounpuu, S.5
Lawton, W.A.6
Palesch, Y.7
Martin, R.H.8
Albers, G.W.9
Bath, P.10
Bornstein, N.11
Chan, B.P.L.12
Chen, S.13
Cunha, L.14
Dahlöf, B.15
De Keyser, J.16
Donnan, G.A.17
Estol, C.18
Gorelick, P.19
Gu, V.20
more..
-
55
-
-
0034235020
-
Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction
-
Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-57.
-
(2000)
J Stroke Cerebrovasc Dis
, vol.9
, pp. 147-157
-
-
Gotoh, F.1
Tohgi, H.2
Hirai, S.3
Terashi, A.4
Fukuuchi, Y.5
Otomo, E.6
Shinohara, Y.7
Itoh, E.8
Matsuda, T.9
Sawada, T.10
Yamaguchi, T.11
Nishimaru, K.12
Ohashi, Y.13
-
56
-
-
43249105908
-
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study
-
Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494-9.
-
(2008)
Lancet Neurol
, vol.7
, pp. 494-499
-
-
Huang, Y.1
Cheng, Y.2
Wu, J.3
Li, Y.4
Xu, E.5
Hong, Z.6
Li, Z.7
Zhang, W.8
Ding, M.9
Gao, X.10
Fan, D.11
Zeng, J.12
Wong, K.13
Lu, C.14
Xiao, J.15
Yao, C.16
-
57
-
-
35248821708
-
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial
-
FASTER Investigators.
-
Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM, FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-9.
-
(2007)
Lancet Neurol
, vol.6
, pp. 961-969
-
-
Kennedy, J.1
Hill, M.D.2
Ryckborst, K.J.3
Eliasziw, M.4
Demchuk, A.M.5
Buchan, A.M.6
-
58
-
-
5444220166
-
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease
-
Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292: 1867-74.
-
(2004)
JAMA
, vol.292
, pp. 1867-1874
-
-
Tran, H.1
Anand, S.S.2
-
59
-
-
65549105821
-
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials
-
Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301: 1909-19.
-
(2009)
JAMA
, vol.301
, pp. 1909-1919
-
-
Berger, J.S.1
Krantz, M.J.2
Kittelson, J.M.3
Hiatt, W.R.4
-
60
-
-
55949127696
-
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
-
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
-
(2008)
BMJ
, vol.337
-
-
Belch, J.1
MacCuish, A.2
Campbell, I.3
Cobbe, S.4
Taylor, R.5
Prescott, R.6
Lee, R.7
Bancroft, J.8
MacEwan, S.9
Shepherd, J.10
Macfarlane, P.11
Morris, A.12
Jung, R.13
Kelly, C.14
Connacher, A.15
Peden, N.16
Jamieson, A.17
Matthews, D.18
Leese, G.19
McKnight, J.20
more..
-
61
-
-
77649198148
-
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial
-
Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH, Sandercock PAG, Fox KAA, Lowe GDO, Murray GD. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-8.
-
(2010)
JAMA
, vol.303
, pp. 841-848
-
-
Fowkes, F.G.R.1
Price, J.F.2
Stewart, M.C.W.3
Butcher, I.4
Leng, G.C.5
Pell, A.C.H.6
Sandercock, P.A.G.7
Fox, K.A.A.8
Lowe, G.D.O.9
Murray, G.D.10
-
62
-
-
77957660699
-
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial
-
833.e1-2.
-
Belch JJF, Dormandy J, Biasi BM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepäntalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825-33, 833.e1-2.
-
(2010)
J Vasc Surg
, vol.52
, pp. 825-833
-
-
Belch, J.J.F.1
Dormandy, J.2
Biasi, B.M.3
Cairols, M.4
Diehm, C.5
Eikelboom, B.6
Golledge, J.7
Jawien, A.8
Lepäntalo, M.9
Norgren, L.10
Hiatt, W.R.11
Becquemin, J.P.12
Bergqvist, D.13
Clement, D.14
Baumgartner, I.15
Minar, E.16
Stonebridge, P.17
Vermassen, F.18
Matyas, L.19
Leizorovicz, A.20
more..
-
63
-
-
77953320338
-
Aspirin for primary prevention of cardiovascular events in people with diabetes
-
Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55: 2878-86.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2878-2886
-
-
Pignone, M.1
Alberts, M.J.2
Colwell, J.A.3
Cushman, M.4
Inzucchi, S.E.5
Mukherjee, D.6
Rosenson, R.S.7
Williams, C.D.8
Wilson, P.W.9
Kirkman, M.S.10
-
64
-
-
35348816110
-
Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
-
De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, Valentini U, Nicolucci A. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8: 21.
-
(2007)
Trials
, vol.8
, pp. 21
-
-
De Berardis, G.1
Sacco, M.2
Evangelista, V.3
Filippi, A.4
Giorda, C.B.5
Tognoni, G.6
Valentini, U.7
Nicolucci, A.8
-
65
-
-
79960623280
-
-
British Heart Foundation. ASCEND: a study of cardiovascular events in diabetes. Accessed 28 April 2011.
-
British Heart Foundation. ASCEND: a study of cardiovascular events in diabetes. Accessed 28 April 2011.
-
-
-
|